In last trading session, Lyell Immunopharma Inc (NASDAQ:LYEL) saw 1.42 million shares changing hands with its beta currently measuring -0.35. Company’s recent per share price level of $0.66 trading at $0.04 or 6.66% at ring of the bell on the day assigns it a market valuation of $192.83M. That closing price of LYEL’s stock is at a discount of -393.94% from its 52-week high price of $3.26 and is indicating a premium of 22.73% from its 52-week low price of $0.51.
For Lyell Immunopharma Inc (LYEL), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 3.33. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 0 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.13 in the current quarter.
Lyell Immunopharma Inc (NASDAQ:LYEL) trade information
Upright in the green during last session for gaining 6.66%, in the last five days LYEL remained trading in the green while hitting it’s week-highest on Thursday, 02/20/25 when the stock touched $0.66 price level, adding 3.69% to its value on the day. Lyell Immunopharma Inc’s shares saw a change of 3.13% in year-to-date performance and have moved 22.95% in past 5-day. Lyell Immunopharma Inc (NASDAQ:LYEL) showed a performance of 16.01% in past 30-days.
Wall Street analysts have assigned a consensus price target of 1 to the stock, which implies a rise of 34.0% to its current value. Analysts have been projecting 1 as a low price target for the stock while placing it at a high target of 1. It follows that stock’s current price would drop -51.52% in reaching the projected high whereas dropping to the targeted low would mean a loss of -51.52% for stock’s current value.
Lyell Immunopharma Inc (LYEL) estimates and forecasts
This year revenue growth is estimated to fall -59.23% from the last financial year’s standing.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -15.28% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 21.51% while estimates for its earnings growth in next 5 years are of 17.62%.
Lyell Immunopharma Inc (NASDAQ:LYEL)’s Major holders
MWG MANAGEMENT LTD. is the top institutional holder at LYEL for having 20.16 million shares of worth $29.24 million. And as of 2024-06-30, it was holding 7.8945 of the company’s outstanding shares.
The second largest institutional holder is ORLAND PROPERTIES LTD, which was holding about 15.09 million shares on 2024-06-30. The number of shares represents firm’s hold over 5.91 of outstanding shares, having a total worth of $21.89 million.
On the other hand, Vanguard Total Stock Market Index Fund and Price (T.Rowe) Health Sciences Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 5.82 shares of worth $3.84 million or 1.99% of the total outstanding shares. The later fund manager was in possession of 5.4 shares on Sep 30, 2024 , making its stake of worth around $3.56 million in the company or a holder of 1.85% of company’s stock.
